Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants

@article{Malkesman2012TargetingTB,
  title={Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants},
  author={Oz Malkesman and Daniel R. Austin and Tyson R Tragon and Ioline D. Henter and John C. Reed and Maurizio Pellecchia and Guang Chen and Husseini K. Manji},
  journal={Molecular Psychiatry},
  year={2012},
  volume={17},
  pages={770-780}
}
The BH3-interacting domain death agonist (Bid) is a pro-apoptotic member of the B-cell lymphoma-2 (Bcl-2) protein family. Previous studies have shown that stress reduces levels of Bcl-2 in brain regions implicated in the pathophysiology of mood disorders, whereas antidepressants and mood stabilizers increase Bcl-2 levels. The Bcl-2 protein family has an essential role in cellular resilience as well as synaptic and neuronal plasticity and may influence mood and affective behaviors. This study… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 70 references

Similar Papers

Loading similar papers…